KR20140067070A - H-포스포네이트에 의한 나노입자 peg 개질 - Google Patents
H-포스포네이트에 의한 나노입자 peg 개질 Download PDFInfo
- Publication number
- KR20140067070A KR20140067070A KR1020147007934A KR20147007934A KR20140067070A KR 20140067070 A KR20140067070 A KR 20140067070A KR 1020147007934 A KR1020147007934 A KR 1020147007934A KR 20147007934 A KR20147007934 A KR 20147007934A KR 20140067070 A KR20140067070 A KR 20140067070A
- Authority
- KR
- South Korea
- Prior art keywords
- group
- agent
- compound
- peg
- stealth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/44—Amides thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/832—Nanostructure having specified property, e.g. lattice-constant, thermal expansion coefficient
- Y10S977/835—Chemical or nuclear reactivity/stability of composition or compound forming nanomaterial
- Y10S977/836—Chemical or nuclear reactivity/stability of composition or compound forming nanomaterial having biological reactive capability
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Polyethers (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161529694P | 2011-08-31 | 2011-08-31 | |
| US61/529,694 | 2011-08-31 | ||
| PCT/US2012/053197 WO2013033438A2 (en) | 2011-08-31 | 2012-08-30 | Nanoparticle peg modification with h-phosphonates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20140067070A true KR20140067070A (ko) | 2014-06-03 |
Family
ID=46888663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020147007934A Withdrawn KR20140067070A (ko) | 2011-08-31 | 2012-08-30 | H-포스포네이트에 의한 나노입자 peg 개질 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8889657B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2750712A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2014527071A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140067070A (cg-RX-API-DMAC7.html) |
| CN (1) | CN103930135A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014004544A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2845845A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL231215A0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013033438A2 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200078962A (ko) * | 2018-12-24 | 2020-07-02 | 연세대학교 산학협력단 | 야누스 펩타이드 덴드리머 및 이의 용도 |
Families Citing this family (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2857499A1 (en) | 2010-10-01 | 2015-04-08 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
| ES2923757T3 (es) | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
| WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
| US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| EP3019559A4 (en) | 2013-08-22 | 2017-04-05 | Sony Corporation | Water soluble fluorescent or colored dyes and methods for their use |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| WO2016011226A1 (en) | 2014-07-16 | 2016-01-21 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| EP3171895A1 (en) | 2014-07-23 | 2017-05-31 | Modernatx, Inc. | Modified polynucleotides for the production of intrabodies |
| HRP20220156T1 (hr) | 2015-09-17 | 2022-04-15 | Modernatx, Inc. | Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava |
| WO2017067592A1 (en) | 2015-10-21 | 2017-04-27 | Biontech Ag | Cytotoxic immunostimulating particles and uses thereof |
| PE20181531A1 (es) | 2015-10-22 | 2018-09-26 | Modernatx Inc | Vacuna del virus herpes simple |
| EP3364981A4 (en) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
| DE20164728T1 (de) | 2015-10-22 | 2021-09-30 | Modernatx, Inc. | Impfstoffe gegen atemwegsvirus |
| US20180271970A1 (en) | 2015-10-22 | 2018-09-27 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
| MA46023A (fr) | 2015-10-22 | 2019-07-03 | Modernatx Inc | Vaccin contre le virus de la grippe à large spectre |
| SG11201803360UA (en) | 2015-10-22 | 2018-05-30 | Modernatx Inc | Nucleic acid vaccines for varicella zoster virus (vzv) |
| DK3386484T3 (da) | 2015-12-10 | 2022-07-04 | Modernatx Inc | Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler |
| RS63051B1 (sr) | 2015-12-22 | 2022-04-29 | Modernatx Inc | Jedinjenja i kompozicije za intracelularnu isporuku agenasa |
| SMT202200310T1 (it) | 2015-12-23 | 2022-09-14 | Modernatx Inc | Metodi di utilizzo dei polinucleotidi codificanti il ligando di ox40 |
| US20190241658A1 (en) | 2016-01-10 | 2019-08-08 | Modernatx, Inc. | Therapeutic mRNAs encoding anti CTLA-4 antibodies |
| BR112018070164B1 (pt) | 2016-04-01 | 2022-09-27 | Sony Corporation Of America | Corantes diméricos ou poliméricos ultrabrilhantes |
| CN109153860B (zh) | 2016-04-06 | 2021-04-23 | 索尼公司 | 具有间隔连接体基团的超高亮二聚体或聚合物染料 |
| BR112018073199A2 (pt) | 2016-05-11 | 2019-04-16 | Sony Corporation | corantes diméricos ou poliméricos ultrabrilhantes |
| WO2018022925A1 (en) | 2016-07-29 | 2018-02-01 | Sony Corporation | Ultra bright dimeric or polymeric dyes and methods for preparation of the same |
| US10072032B2 (en) | 2016-09-19 | 2018-09-11 | Afton Chemical Corporation | AminoBisPhosphonate antiwear additives |
| EP3538067A1 (en) | 2016-11-08 | 2019-09-18 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| RS63953B1 (sr) | 2017-03-15 | 2023-02-28 | Modernatx Inc | Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava |
| WO2018170322A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
| JP7332478B2 (ja) | 2017-03-15 | 2023-08-23 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子製剤 |
| AU2018270111B2 (en) | 2017-05-18 | 2022-07-14 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof |
| EP4253544A3 (en) | 2017-05-18 | 2023-12-20 | ModernaTX, Inc. | Modified messenger rna comprising functional rna elements |
| EP3638678B1 (en) | 2017-06-14 | 2025-12-03 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of agents |
| EP3638292A1 (en) | 2017-06-14 | 2020-04-22 | ModernaTX, Inc. | Polynucleotides encoding coagulation factor viii |
| MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
| MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
| US12290571B2 (en) | 2017-10-05 | 2025-05-06 | Sony Group Corporation | Programmable dendritic drugs |
| KR20260011205A (ko) | 2017-10-05 | 2026-01-22 | 소니그룹주식회사 | 프로그램가능한 중합체성 약물 |
| CN111836645A (zh) | 2017-11-16 | 2020-10-27 | 索尼公司 | 可编程的聚合药物 |
| US11939601B2 (en) | 2017-11-22 | 2024-03-26 | Modernatx, Inc. | Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria |
| JP7424976B2 (ja) | 2017-11-22 | 2024-01-30 | モダーナティエックス・インコーポレイテッド | プロピオン酸血症の治療用のプロピオニルCoAカルボキシラーゼアルファ及びベータサブユニットをコードするポリヌクレオチド |
| EP3714048B1 (en) | 2017-11-22 | 2025-04-09 | ModernaTX, Inc. | Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders |
| US11802146B2 (en) | 2018-01-05 | 2023-10-31 | Modernatx, Inc. | Polynucleotides encoding anti-chikungunya virus antibodies |
| WO2019140128A1 (en) | 2018-01-12 | 2019-07-18 | Sony Corporation | Phosphoalkyl polymers comprising biologically active compounds |
| EP3737417B1 (en) | 2018-01-12 | 2025-08-27 | Sony Group Corporation | Phosphoalkyl ribose polymers comprising biologically active compounds |
| US12076407B2 (en) | 2018-01-12 | 2024-09-03 | Sony Group Corporation | Polymers with rigid spacing groups comprising biologically active compounds |
| US20190262793A1 (en) * | 2018-02-28 | 2019-08-29 | Southwest Research Institute | Polymer-Encapsulated Polyhemoglobin-Based Oxygen Carrier |
| EP3769085B1 (en) | 2018-03-19 | 2022-08-24 | Sony Group Corporation | Use of divalent metals for enhancement of fluorescent signals |
| KR102864292B1 (ko) | 2018-03-21 | 2025-09-26 | 소니그룹주식회사 | 링커 군을 갖는 중합체성 텐덤 염료 |
| US20210163928A1 (en) | 2018-04-11 | 2021-06-03 | Modernatx, Inc. | Messenger rna comprising functional rna elements |
| MA52709A (fr) | 2018-05-23 | 2021-03-31 | Modernatx Inc | Administration d'adn |
| JP7580689B2 (ja) | 2018-06-27 | 2024-11-12 | ソニーグループ株式会社 | デオキシリボースを含むリンカー基を有するポリマー色素 |
| US12578342B2 (en) | 2018-07-13 | 2026-03-17 | Sony Group Corporation | Polymeric dyes having a backbone comprising organophosphate units |
| WO2020023390A1 (en) | 2018-07-25 | 2020-01-30 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
| MA53545A (fr) | 2018-09-02 | 2021-07-14 | Modernatx Inc | Polynucléotides codant pour l'acyl-coa déshydrogénase à très longue chaîne pour le traitement de l'insuffisance en acyl-coa déshydrogénase à très longue chaîne |
| US20220054610A1 (en) | 2018-09-12 | 2022-02-24 | University Of Florida Research Foundation, Inc. | Slow-cycling cell-rna based nanoparticle vaccine to treat cancer |
| JP2022500436A (ja) | 2018-09-13 | 2022-01-04 | モダーナティエックス・インコーポレイテッドModernaTX, Inc. | 糖原病を処置するためのグルコース−6−ホスファターゼをコードするポリヌクレオチド |
| US12644102B2 (en) | 2018-09-13 | 2026-06-02 | Modernatx, Inc. | Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex E1-α, E1-β, and E2 subunits for the treatment of maple syrup urine disease |
| MA53615A (fr) | 2018-09-14 | 2021-07-21 | Modernatx Inc | Polynucléotides codant pour le polypeptide a1, de la famille de l'uridine diphosphate glycosyltransférase 1, pour le traitement du syndrome de crigler-najjar |
| EP3853202A1 (en) | 2018-09-19 | 2021-07-28 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| US12151029B2 (en) | 2018-09-19 | 2024-11-26 | Modernatx, Inc. | PEG lipids and uses thereof |
| CN112996854B (zh) | 2018-09-19 | 2024-08-30 | 摩登纳特斯有限公司 | 高纯度peg脂质和其用途 |
| US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| WO2020069169A1 (en) | 2018-09-27 | 2020-04-02 | Modernatx, Inc. | Polynucleotides encoding arginase 1 for the treatment of arginase deficiency |
| MX2021003726A (es) * | 2018-10-01 | 2021-05-13 | BioNTech SE | Particulas de arn que comprenden polisarcosina. |
| WO2020069718A1 (en) * | 2018-10-01 | 2020-04-09 | Johannes Gutenberg-Universität Mainz | Rna particles comprising polysarcosine |
| US20220001026A1 (en) | 2018-11-08 | 2022-01-06 | Modernatx, Inc. | Use of mrna encoding ox40l to treat cancer in human patients |
| CN113939282A (zh) | 2019-01-31 | 2022-01-14 | 摩登纳特斯有限公司 | 制备脂质纳米颗粒的方法 |
| EP3962521A1 (en) | 2019-05-02 | 2022-03-09 | University of Florida Research Foundation, Inc. | Compositions for treatment of diffuse intrinsic pontine glioma |
| WO2020227615A1 (en) | 2019-05-08 | 2020-11-12 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia |
| WO2020227642A1 (en) | 2019-05-08 | 2020-11-12 | Modernatx, Inc. | Compositions for skin and wounds and methods of use thereof |
| MA56517A (fr) | 2019-06-24 | 2022-04-27 | Modernatx Inc | Arn messager comprenant des éléments d'arn fonctionnels et leurs utilisations |
| EP3987027A1 (en) | 2019-06-24 | 2022-04-27 | ModernaTX, Inc. | Endonuclease-resistant messenger rna and uses thereof |
| AU2020351220A1 (en) | 2019-09-19 | 2022-04-07 | Modernatx, Inc. | Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents |
| EP4031524A1 (en) | 2019-09-19 | 2022-07-27 | ModernaTX, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| EP3861074A2 (en) | 2019-09-26 | 2021-08-11 | Sony Group Corporation | Polymeric tandem dyes with linker groups |
| EP4038081A1 (en) | 2019-09-30 | 2022-08-10 | Sony Group Corporation | Nucleotide probes |
| AU2021285812A1 (en) | 2020-06-01 | 2023-01-05 | Modernatx, Inc. | Phenylalanine hydroxylase variants and uses thereof |
| JP2023533174A (ja) | 2020-06-12 | 2023-08-02 | ユニバーシティ オブ ロチェスター | ACE-tRNAのコード化及び発現 |
| CA3199784A1 (en) | 2020-11-13 | 2022-05-19 | Modernatx, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
| EP4256078A1 (en) | 2020-12-07 | 2023-10-11 | Sony Group Corporation | Spacing linker group design for brightness enhancement in dimeric or polymeric dyes |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| WO2022204369A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia |
| US20240207374A1 (en) | 2021-03-24 | 2024-06-27 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof |
| WO2022204380A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof |
| WO2022204390A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof |
| US20240189449A1 (en) | 2021-03-24 | 2024-06-13 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency |
| US20240384277A1 (en) | 2021-06-15 | 2024-11-21 | Modernatx, Inc. | Engineered polynucleotides for cell-type or microenvironment-specific expression |
| US20240376445A1 (en) | 2021-06-22 | 2024-11-14 | Modernatx, Inc. | Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome |
| US20250017867A1 (en) | 2021-10-01 | 2025-01-16 | Modernatx, Inc. | Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease |
| AU2023215397A1 (en) | 2022-02-07 | 2024-08-22 | University Of Rochester | Optimized sequences for enhanced trna expression or/and nonsense mutation suppression. |
| US20250327041A1 (en) | 2022-02-24 | 2025-10-23 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
| WO2023177904A1 (en) | 2022-03-18 | 2023-09-21 | Modernatx, Inc. | Sterile filtration of lipid nanoparticles and filtration analysis thereof for biological applications |
| WO2023183909A2 (en) | 2022-03-25 | 2023-09-28 | Modernatx, Inc. | Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia |
| WO2023196399A1 (en) | 2022-04-06 | 2023-10-12 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding argininosuccinate lyase for the treatment of argininosuccinic aciduria |
| WO2023215498A2 (en) | 2022-05-05 | 2023-11-09 | Modernatx, Inc. | Compositions and methods for cd28 antagonism |
| KR20250019125A (ko) | 2022-06-02 | 2025-02-07 | 젤리스트 인코퍼레이티드 | 고순도 알킬 주석 화합물 및 이의 제조 방법 |
| EP4562163A1 (en) | 2022-07-26 | 2025-06-04 | ModernaTX, Inc. | Engineered polynucleotides for temporal control of expression |
| WO2024044147A1 (en) | 2022-08-23 | 2024-02-29 | Modernatx, Inc. | Methods for purification of ionizable lipids |
| US12606577B2 (en) | 2022-09-28 | 2026-04-21 | Gelest, Inc. | Iodoalkyl tin compounds and preparation methods thereof |
| WO2024097639A1 (en) | 2022-10-31 | 2024-05-10 | Modernatx, Inc. | Hsa-binding antibodies and binding proteins and uses thereof |
| US20260191905A1 (en) | 2022-12-01 | 2026-07-09 | Modernatx, Inc. | Gpc3-specific antibodies, binding domains, and related proteins and uses thereof |
| WO2024197033A1 (en) | 2023-03-21 | 2024-09-26 | Modernatx, Inc. | Polynucleotides encoding relaxin for the treatment of heart failure |
| EP4704816A1 (en) | 2023-05-03 | 2026-03-11 | ModernaTX, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
| EP4520345A1 (en) | 2023-09-06 | 2025-03-12 | Myneo Nv | Product |
| WO2025072482A1 (en) | 2023-09-27 | 2025-04-03 | Modernatx, Inc. | Immunoglobulin a protease polypeptides, polynucleotides, and uses thereof |
| WO2025101685A1 (en) | 2023-11-09 | 2025-05-15 | University Of Rochester | Suppression of nonsense mutations using anticodon engineered (ace)-trnas |
| WO2025115332A1 (ja) | 2023-12-01 | 2025-06-05 | 三菱ケミカル株式会社 | スズ化合物およびそれを用いたレジスト溶液、パターン形成方法、薄膜、パターン化された薄膜、並びにスズ化合物の製造方法 |
| WO2025255199A1 (en) | 2024-06-05 | 2025-12-11 | Modernatx, Inc. | Argininosuccinate synthase 1 and argininosuccinate lyase polypeptides and polynucleotides and uses thereof |
| WO2026030209A1 (en) | 2024-07-29 | 2026-02-05 | University Of Rochester | Use of decoding trnas to boost protein expression or function |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE514095C (de) * | 1927-07-24 | 1930-12-11 | Knoll Akt Ges Chemische Fabrik | Verfahren zur Herstellung von Estern der Sterine mit Sauerstoffsaeuren des Phosphors |
| CH336065A (de) * | 1954-03-05 | 1959-02-15 | Ciba Geigy | Verfahren zur Herstellung von neuen Stickstoff und Phosphor enthaltenden Verbindungen |
| GB1128086A (en) * | 1966-10-27 | 1968-09-25 | Pure Chem Ltd | Improvements relating to hydroxy-containing phosphonates and polyurethanes |
| US3974209A (en) * | 1971-08-04 | 1976-08-10 | Monsanto Company | Substituted tertiary amines and processes for preparing the same |
| DE3202127A1 (de) * | 1982-01-23 | 1983-07-28 | Agfa-Gevaert Ag, 5090 Leverkusen | Fotografisches material mit einer durch organische farbstoffe anfaerbbaren schicht |
| US4568432A (en) | 1984-12-28 | 1986-02-04 | Monsanto Company | Process for preparing glyphosate and glyphosate derivatives |
| EP0209848A3 (en) * | 1985-07-24 | 1988-07-27 | Merck & Co. Inc. | Enzyme inhibitors |
| US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
| DE4408729A1 (de) * | 1994-03-15 | 1995-09-21 | Hoechst Ag | Nichtcyclische Chelatbildner auf Basis von Aminodialkylphosphoroxiden zur Herstellung von Technetium- oder Rheniumkomplexen |
| US6054608A (en) | 1997-05-05 | 2000-04-25 | Monsanto Company | Method for preparing formylphosphonic acid |
| ZA989394B (en) * | 1997-10-15 | 1999-04-15 | Monsanto Co | Selective functionalization of sodium glycinate |
| JP3799435B2 (ja) * | 1998-04-13 | 2006-07-19 | 三共有機合成株式会社 | 安定化された抗菌性樹脂組成物 |
| US7833992B2 (en) * | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
| DE10049074A1 (de) | 2000-10-02 | 2002-04-18 | Andreas Kage | Verfahren zur Selektion hochaffin an ein Target bindender Nukleinsäuren |
| JP2004536034A (ja) * | 2001-01-08 | 2004-12-02 | ネオルクス コーポレイション | 治療的および診断的化合物、組成物および方法 |
| DE10259935A1 (de) * | 2002-12-20 | 2004-07-01 | Bayer Ag | Herstellung und Verwendung von in-situ-modifizierten Nanopartikeln |
| EP1615639A2 (en) * | 2003-04-03 | 2006-01-18 | Semafore Pharmaceuticals, Inc. | Targeted bone marrow protection agents |
| WO2004089925A1 (en) * | 2003-04-03 | 2004-10-21 | Semafore Pharmaceuticals, Inc. | Pi-3 kinase inhibitor prodrugs |
| JP2010535701A (ja) * | 2003-04-25 | 2010-11-25 | ギリアード サイエンシーズ, インコーポレイテッド | 抗癌ホスホネートアナログ |
| DE10320071A1 (de) * | 2003-05-05 | 2004-12-02 | Basf Ag | Alkoxygruppen aufweisende Ester von Phosphor-Sauerstoff-Säuren und ihre Verwendung als Korrosionsinhibitoren |
| US7420000B2 (en) * | 2003-09-10 | 2008-09-02 | University Of Southern California | Amino phosphonate and amino bis-phosphonate derivatives |
| DE102004032781A1 (de) * | 2004-01-23 | 2005-08-11 | Mcs Micro Carrier Systems Gmbh | Bisphosphonsäurederivate |
| US20100015041A1 (en) | 2005-01-18 | 2010-01-21 | Caltagirone Gaetano T | Class of Supramolecular Drug Molecules and Methods of Identification and Use Thereof |
| CA2599673A1 (en) * | 2005-03-08 | 2006-09-14 | Reinhold Oehrlein | Metal oxide nanoparticles coated with specific n-acylaminomethylene phosphonates |
| WO2009066513A1 (ja) * | 2007-11-19 | 2009-05-28 | The University Of Tokyo | 標的核酸を位置選択的に切断する方法 |
| WO2010013086A1 (en) * | 2008-08-01 | 2010-02-04 | Centre National De La Recherche Scientifique | Phosphorylated dendrimers as antiinflammatory drugs |
| EP3699172A3 (en) * | 2008-11-10 | 2020-11-18 | Arbutus Biopharma Corporation | Novel lipids and compositions for the delivery of therapeutics |
| JP5381269B2 (ja) * | 2009-04-15 | 2014-01-08 | コニカミノルタ株式会社 | 光学フィルム、光学フィルムの製造方法、偏光板及び液晶表示装置 |
| CA2825424A1 (en) | 2010-02-08 | 2011-08-11 | Board Of Regents Of The University Of Nebraska | Biomineral and metal binding liposomes, their synthesis, and methods of use thereof |
| CN102858851A (zh) * | 2010-02-18 | 2013-01-02 | 阿尔卡拉德埃纳雷斯大学 | 碳硅烷树枝状化合物及其作为抗病毒剂的用途 |
| JO3131B1 (ar) | 2010-04-27 | 2017-09-20 | Glaxosmithkline Llc | مركبات كيميائية |
| CN102093421B (zh) * | 2011-01-28 | 2014-07-02 | 北京康辰药业有限公司 | 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
-
2012
- 2012-08-30 KR KR1020147007934A patent/KR20140067070A/ko not_active Withdrawn
- 2012-08-30 CN CN201280053606.0A patent/CN103930135A/zh active Pending
- 2012-08-30 BR BR112014004544A patent/BR112014004544A2/pt not_active IP Right Cessation
- 2012-08-30 CA CA2845845A patent/CA2845845A1/en not_active Abandoned
- 2012-08-30 WO PCT/US2012/053197 patent/WO2013033438A2/en not_active Ceased
- 2012-08-30 EP EP12762126.6A patent/EP2750712A2/en not_active Withdrawn
- 2012-08-30 US US13/599,819 patent/US8889657B2/en not_active Expired - Fee Related
- 2012-08-30 JP JP2014528610A patent/JP2014527071A/ja active Pending
-
2014
- 2014-02-27 IL IL231215A patent/IL231215A0/en unknown
- 2014-10-14 US US14/513,994 patent/US20150030541A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200078962A (ko) * | 2018-12-24 | 2020-07-02 | 연세대학교 산학협력단 | 야누스 펩타이드 덴드리머 및 이의 용도 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014527071A (ja) | 2014-10-09 |
| CN103930135A (zh) | 2014-07-16 |
| BR112014004544A2 (pt) | 2017-04-04 |
| CA2845845A1 (en) | 2013-03-07 |
| EP2750712A2 (en) | 2014-07-09 |
| US20150030541A1 (en) | 2015-01-29 |
| WO2013033438A3 (en) | 2013-04-25 |
| US8889657B2 (en) | 2014-11-18 |
| US20130066086A1 (en) | 2013-03-14 |
| WO2013033438A2 (en) | 2013-03-07 |
| IL231215A0 (en) | 2014-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8889657B2 (en) | Nanoparticle PEG modification with H-phosphonates | |
| JP5927194B2 (ja) | 治療ナノキャリアおよび/または診断ナノキャリアのターゲティングのためのアプタマーコンジュゲート | |
| DK2501415T3 (en) | Liposomal nanoparticles of magnetic resonance imaging of tumors | |
| JP6294456B2 (ja) | 修飾されたドセタキセルリポソーム製剤 | |
| KR20140096080A (ko) | Mmp-표적 치료 및/또는 진단 나노담체 | |
| KR20140069269A (ko) | 상보성 올리고뉴클레오티드 링커를 사용한 표적화된 나노입자들의 원격 조립 | |
| CA3002168C (en) | Polyrotaxanes bearing mixed cyclodextrin species and uses thereof | |
| KR20140064917A (ko) | H-포스포네이트-엔/-인 히드로포스포닐화 반응을 이용한 표적화된 나노입자의 원격 어셈블리 | |
| US20150017098A1 (en) | Carrier that targets fucosylated molecule-producing cells | |
| US20170165382A1 (en) | Nanocarriers for cancer treatment | |
| KR20240145481A (ko) | 방사선 민감화 조성물 및 이의 사용 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20140326 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |